What type of study is this?

Angiotensin receptor-neprilysin inhibitors and mortality among patients with HFrEF

View Full Paper

Ask AI

Bookmark

ARNI use is linked to a 15% reduction in all-cause mortality compared to ACE-I/ARB therapy, highlighting potential benefits.
The hazard ratio for all-cause mortality in ARNI initiators is 0.85, indicating a significant reduction in deaths in these patients.
Patients with recent hospitalization showed enhanced benefit from ARNI, underscoring the importance of this intervention in severe cases.
While ARNI is associated with lower cardiovascular death, it does not impact other secondary outcomes, suggesting focused efficacy.

No takes yet. Share an insight, caveat, or question.

Nationwide analysis shows ARNI reduces all-cause mortality compared to ACE-I/ARB in patients with HFrEF, suggesting clinical efficacy.

Svanström et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark